

Neurological Soft Signs in Schizophrenia: A Meta-analysis

Raymond C. K. Chan^{1–3}, Ting Xu^{2,4,5},
R. Walter Heinrichs⁶, Yue Yu^{2,7}, and Ya Wang^{2,3}

²Neuropsychology and Applied Cognitive Neurosciences Laboratory, Institute of Psychology; ³Key Laboratory of Mental Health, Institute of Psychology; ⁴Graduate School, Chinese Academy of Sciences, Beijing, China; ⁵School of Information, Renmin University of China, Beijing, China; ⁶Department of Psychology, York University, Toronto, Canada; ⁷Department of Psychology and Yuanpei College, Peking University, Beijing, China

Background: Neurological soft signs (NSS) are hypothesized as candidate endophenotypes for schizophrenia, but their prevalence and relations with clinical and demographic data are unknown. The authors undertook a quantification (meta-analysis) of the published literature on NSS in patients with schizophrenia and healthy controls. A systematic search was conducted for published articles reporting NSS and related data using standard measures in schizophrenia and healthy comparison groups. **Method:** A systematic search was conducted for published articles reporting data on the prevalence of NSS in schizophrenia using standard clinical rating scales and healthy comparison groups. Meta-analyses were performed using the Comprehensive Meta-analysis software package. Effect sizes (Cohen *d*) indexing the difference between schizophrenic patients and the healthy controls were calculated on the basis of reported statistics. Potential moderator variables evaluated included age of patient samples, level of education, sample sex proportions, medication doses, and negative and positive symptoms. **Results:** A total of 33 articles met inclusion criteria for the meta-analysis. A large and reliable group difference (Cohen *d*) indicated that, on average, a majority of patients (73%) perform outside the range of healthy subjects on aggregate NSS measures. Cognitive performance and positive and negative symptoms share 2%–10% of their variance with NSS. **Conclusions:** NSS occur in a majority of the schizophrenia patient population and are largely distinct from symptomatic and cognitive features of the illness.

Key words: neurological soft signs/meta-analysis/schizophrenia

¹To whom correspondence should be addressed; Institute of Psychology, Chinese Academy of Sciences, 4A Datun Road, Beijing 100101, China; tel/fax: +86-0-10-64836274, e-mail: rckchan@psych.ac.cn.

Introduction

Schizophrenia is a loose and complex neuropsychiatric syndrome characterized by a range of cognitive¹ and psychophysiological deficits.² Beginning with the seminal review by Heinrichs and Buchanan,³ the study of neurological soft signs (NSS) has provided an additional and increasingly important perspective on the illness. Conventionally defined as nonlocalizing abnormalities without diagnostic specificity, NSS involve observable defects in sensory integration (SI), motor coordination (MC), and inhibition. Tsuang and colleagues^{4,5} have argued that these defects reflect genetic and nongenetic processes underpinning the predisposition to psychotic illness. Moreover, the assumption of nonfocal neural representation is being revised in light of evidence that NSS have identifiable cerebral correlates.^{6–8} Current views consider these signs as covariates of attention,^{9–13} verbal ability,^{14,15} and visual-spatial memory.^{10,16,17} It follows that NSS and cognitive findings have emerged as candidate endophenotypes for schizophrenia-spectrum disorders.^{18,19}

Evaluating the strength of evidence in support of NSS as key indicators of psychotic illness has been complicated by a number of potentially confounding variables including duration of illness, medication doses, and the use of different measurement techniques. Although systematic reviews addressing the issues of NSS in schizophrenia have appeared in the past decades, all were narrative reviews (eg, Bombin et al,¹⁸ Heinrichs and Buchanan,³ Bombin et al²⁰). Although valuable, narrative reviews do not quantify the strength or consistency of evidence in a field or test hypotheses about moderators underlying the variability between study findings. Meta-analytic techniques of research synthesis provide the most objective way of assessing the magnitude and consistency of differences between people with and without schizophrenia.^{21,22} Research synthesis aggregates data on the same or highly similar dependent measures from multiple independent studies, expresses differences between schizophrenia patients and healthy comparison subjects in pooled SD units (ie, the effect size), and yields CIs for mean effect sizes.²³

Recent meta-analyses suggest that deficits in cognitive measures consistently distinguish a majority of schizophrenia patients from healthy, nonpsychiatric

subjects.^{21,24,25} However, little is known about the relative prevalence of NSS in schizophrenia patients and healthy samples. In addition, there are a few published estimates of the strength of association between soft signs, symptoms, and neurocognitive functions in the schizophrenia population. Moreover, the relative prevalence of NSS in relatives of schizophrenia patients remains unknown in terms of quantification and consistency across the research literature. Thus, although NSS are regarded as candidate endophenotypes for schizophrenia, it is not clear whether data obtained from relatives parallel the deficits found in patients.

In light of these considerations, we undertook a meta-analysis to address a number of issues concerning the magnitude, consistency, and mediation of NSS in schizophrenia. First, we aimed to determine the average standardized difference in NSS between patients with schizophrenia and healthy research participants. Second, we were interested in estimating the average magnitude of association between NSS, psychiatric symptoms, and neurocognitive functions in the schizophrenia population. Third, we sought to evaluate potential moderator variables that may contribute to differences between patients and healthy participants. These moderators included patients' ages, level of education, sex, medication, and negative and positive symptom severity.

Methods

Potential articles were identified through a comprehensive search using literature databases of Elsevier Science, EBSCOHost (PsychINFO, PsychARTICLE), and MedLine between 1966 and January 2008. The key words were "neurological soft signs," "neurological signs," "soft signs," "neurological abnormality*," "motor coordination," "sensory integration," "disinhibition," "complex motor sequencing," "Luria task," "fist-edge-palm," "schizophrenia," "schizotypal," and "schizotypy." Additional articles were obtained from the reference lists of the initial article base and from a search from January 2007 through January 2008 of journals that frequently published articles on NSS in schizophrenia. This strategy was used to minimize the possibility of overlooking very recent articles not included in computerized databases. These journals included *Acta Psychiatrica Scandinavica*, *American Journal of Psychiatry*, *Archives of General Psychiatry*, *British Journal of Psychiatry*, *Journal of Abnormal Psychology*, *European Archives of Psychiatry and Clinical Neuroscience*, *Journal of Nervous and Mental Diseases*, *Neuropsychology*, *Neuropsychologia*, *Psychiatry Research*, *Psychological Medicine*, *Schizophrenia Bulletin*, and *Schizophrenia Research*. These search procedures yielded an initial pool of 172 potential articles for inclusion.

The following criteria were used to select studies in the initial pool for quantitative analysis. Each study required

at least one of the criteria: (1) patients and controls' scores means or *t* value obtained from NSS instruments such as the Neurological Evaluation Scale (NES)²⁶ and the Cambridge Neurological Inventory (CNI)²⁷; (2) the correlation coefficient between NSS and psychiatric symptom ratings from instruments including the Brief Psychiatric Rating Scale (BPRS),²⁸ Positive and Negative Syndrome Scale (PANSS),²⁹ the Scale for Assessment of Positive Symptoms,³⁰ and the Scale for Assessment of Negative Symptoms³¹; and (3) the correlation coefficient between NSS and scores of neurocognitive performance from standard tests such as the Wechsler Adult Intelligence Scale,^{32,33} Trail Making Test,³⁴ and Wisconsin Card Sorting Test,³⁵ etc.

This procedure yielded a study base of 57 published reports, with 40 contrasting NSS (included total and subscale) schizophrenic and healthy control samples, 14 reporting correlation coefficients between NSS and neurocognitive scores, and 18 reports of correlation coefficients between NSS and symptom scores.

We recorded potential moderator variables including (1) the name of the first author, year of publication, and the order for sorting; (2) schizophrenia diagnostic criteria used (*Diagnostic and Statistical Manual of Mental Disorders* [Third Edition], *Diagnostic and Statistical Manual of Mental Disorders* [Third Edition Revised], or *Diagnostic and Statistical Manual of Mental Disorders* [Fourth Edition]; *International Classification of Diseases, Ninth Revision or Tenth Revision*); (3) descriptions of basic information including sample size, gender, age, education, age on set, duration of illness, chronic vs first-episode schizophrenia; (4) NSS scale (ie, NES, CNI, Condensed Neurological Examination,³⁶ etc) and NSS score of patients and controls (mean, SD, *t* value, *P* value); (5) correlation coefficient comparing patients' NSS scores with their symptoms scores; and (6) correlation coefficient comparing patients' NSS scores with their neurocognitive function test score.

Data Analysis

All analyses were performed using the Comprehensive Meta-analysis (CMA) software package.³⁷ Effect sizes (Cohen *d*) indexing the difference between schizophrenia patients and the healthy controls were calculated on the basis of reported statistics (mean of schizophrenia sample minus the mean of the healthy control group, divided by the pooled SD). When means and SDs were not available, effect size *d* was computed from *t* or *F* values or estimated from exact *P* values. Standard meta-analytic methods were adopted to obtain mean effect sizes weighted for study variance and averaged across primary studies.²³ Stability of the mean effect was estimated by its 95% CI. In addition, the homogeneity statistic, *Q*, was calculated to test whether individual study effect sizes for any given variable likely reflect a single common population effect size. A significant *Q* statistic indicates heterogeneity

Table 1. Results of Meta-analyses of Differences in NSS Total Scores and Subscale Scores Between Schizophrenia Patients and Healthy Controls

	Number of Studies	Number of Schizophrenic Patients	Number of Healthy Controls	Std Diff	SE (95% CI)	Q Value	Fail-Safe N
Contrasting NSS total score	33	2345	1984	1.591	0.109 (1.377, 1.805)	277.093*	341
NSS measured by NES or modified NES	22	1382	1229	1.554	0.137 (1.285, 1.822)	170.285*	219
NSS measured by CNI	5	688	553	1.404	0.275 (0.866, 1.943)	65.172*	47
First-episode schizophrenia only	9	646	717	1.526	0.238 (1.060, 1.992)	97.806*	74
Chronic/mixed	24	1699	1267	1.613	0.120 (1.378, 1.848)	160.826*	272
Contrasting NSS-MC score	24	1926	1510	0.977	0.094 (0.793, 1.161)	128.686*	175
NSS measured by NES or modified NES	14	990	742	0.878	0.088 (0.705, 1.051)	31.253	93
NSS measured by CNI	8	871	728	1.110	0.211 (0.697, 1.523)	93.596*	64
First-episode schizophrenia only	7	661	610	0.968	0.140 (0.693, 1.242)	26.016*	51
Chronic/mixed	17	1265	900	0.979	0.126 (0.731, 1.226)	102.661*	125
Contrasting NSS-SI score	23	1839	1456	0.823	0.087 (0.652, 0.994)	104.487*	106
NSS measured by NES or modified NES	15	1022	774	0.872	0.122 (0.633, 1.111)	68.838*	65
NSS measured by CNI	7	778	660	0.739	0.140 (0.464, 1.014)	33.144*	34
First-episode schizophrenia only	7	600	574	0.754	0.170 (0.421, 1.086)	35.659*	22
Chronic/mixed	16	1239	882	0.854	0.100 (0.659, 1.049)	58.989*	88
Contrasting NSS-MSeq (NES) score	15	1001	721	0.795	0.127 (0.546, 1.044)	71.407*	62
First-episode schizophrenia only	6	482	414	0.677	0.204 (0.276, 1.078)	31.001*	16
Chronic/mixed	9	519	307	0.874	0.156 (0.569, 1.179)	30.220*	54
Contrasting NSS-disinhib (CNI) score	8	909	711	0.970	0.180 (0.617, 1.322)	69.388*	56

Note: NSS = neurological soft signs; Std Diff = standard difference in means; NES = Neurological Evaluation Scale; CNI = Cambridge Neurological Inventory; MC = motor coordination; SI = sensory integration; MSeq = complex motor sequencing; disinhib = disinhibition.

*Q value heterogeneous, $P < .05$.

of the individual study effect sizes, implying multiple underlying effect populations and the need to analyze potential moderators of effect size variability.²³

Due to the existence of the hypothetical “file-drawer problem,”³⁸ whereby mean effect sizes based on published findings may be overturned by the existence of discrepant unpublished findings,³⁹ it is recommended that researchers use estimation procedures to assess the likelihood of this possibility. Thus, a fail-safe number estimates the number of unpublished studies with nil or minimal effect sizes required to reduce an overall effect size to some specified negligible value.^{38,40} We set this negligible level at 0.2 and assumed a value of 0.1 for hypothetically “missing” or unpublished studies. A second method is a 2-step approach that uses both visual inspection of graphic data and estimation procedures. First, individual study effect sizes are plotted against their SEs, giving rise to a “funnel” shape or distribution in the ideal situation and suggesting the absence of bias. On the other hand, skewing and asymmetry in the effect distribution imply a publication bias.⁴¹ Duval and Tweedie⁴² developed a method whereby “miss-

ing” study effects that correct the hypothetical bias and graphic asymmetry are estimated and included along with the published studies to yield an adjusted mean effect size. This procedure was carried out with the CMA software. Finally, moderator variables evaluated in relation to both uncorrected and corrected effect sizes included age of patient samples, level of education, sample sex proportions, medication doses, and negative and positive symptoms.

Results

The primary study base yielded 34 schizophrenia-control comparisons of NSS total score data drawn from 33 independent studies. One study⁴³ was excluded because it reported the same data as Ismail et al,⁴⁴ which was included in the study base. All these comparisons were reported as being statistically significant in the original studies. Grand mean effect sizes for total and selective NSS scores along with their 95% CIs and homogeneity statistics are presented in table 1. The aggregated NSS




Fig. 1. Funnel Plot for the Meta-analysis of Differences in Neurological Soft Signs Total Scores Between Schizophrenia Patients and Healthy Controls.

total score mean effect was large, corresponding to 73% separation of joint schizophrenia and control distributions.⁴⁵ However, the individual effects were not homogeneous as indexed by the *Q* statistic. Moreover, the funnel plot (figure 1) showed a higher concentration of studies on the right side of the mean, suggesting a bias against publishing small studies with no effect. Therefore, the CMA recomputed the effect size using the method of

Duval and Tweedie⁴⁰ described previously. The number of “missing” studies and adjusted effect size and adjusted *Q* statistic are shown in table 2. The adjusted standard difference in means is lower than uncorrected results for NSS total and for every subscale comparison. Nevertheless, the fail-safe number of studies required to overturn the mean effect size was 341, which is sufficiently large to make the existence of large numbers of unpublished negligible findings unlikely. Analysis of data derived from first-episode schizophrenia and chronic patient samples also revealed large mean effect sizes that were statistically indistinguishable. Similarly, there was no evidence for greater sensitivity of type of NSS instrument (ie, NES vs CNI). However, mean *d*'s and associated CIs show that NSS indexed by a total score, rather than subscales indexing sensory and motor items, provides the most sensitive discrimination of patients and controls. Mean effect sizes for all subscale scores were less than *d* = 1.0. At the same time, all quantified literatures with the exception of studies reporting MC subscale scores based on the NES revealed significant heterogeneity as indexed by *Q* tests (figures 1–4).

Pearson correlation coefficients between NSS total and subscale scores and aggregated and selective neurocognitive test scores are presented in tables 3 and 4. Several literatures were represented by small numbers of primary studies.^{11,13,15,17,46–50} However, it is noteworthy that NSS

Table 2. Adjusted Results of Meta-analyses of Differences in NSS Total Scores and Subscale Scores Between Schizophrenia Patients and Healthy Controls

	Number of Studies Missing	Adjusted Std Diff (Adjusted 95% CI)	Adjusted <i>Q</i> Value
Contrasting NSS total score	14	1.077 (0.844, 1.310)	561.558*
NSS measured by NES or modified NES	9	1.041 (0.751, 1.331)	342.637*
NSS measured by CNI	2	0.950 (0.339, 1.561)	144.857*
First-episode schizophrenia only	4	0.848 (0.340, 1.357)	205.437*
Chronic/mixed	10	1.176 (0.918, 1.433)	332.353*
Contrasting NSS-MC score	8	0.726 (0.512, 0.941)	308.755*
NSS measured by NES or modified NES	3	0.749 (0.550, 0.948)	62.317*
NSS measured by CNI	2	0.838 (0.381, 1.295)	175.308*
First-episode schizophrenia only	3	0.757 (0.447, 1.066)	66.126*
Chronic/mixed	0	—	—
Contrasting NSS-SI score	11	0.516 (0.332, 0.700)	232.101*
NSS measured by NES or modified NES	7	0.517 (0.267, 0.768)	139.946*
NSS measured by CNI	0	—	—
First-episode schizophrenia only	3	0.432 (0.085, 0.780)	67.380*
Chronic/mixed	2	0.755 (0.539, 0.971)	82.997*
Contrasting NSS-Mseq (NES) score	7	0.389 (0.116, 0.663)	183.344*
First-episode schizophrenia only	3	0.234 (−0.196, 0.664)	86.628*
Chronic/mixed	1	0.777 (0.440, 1.113)	41.204*
Contrasting NSS-disinhib (CNI) score	2	0.710 (0.287, 1.132)	169.308*

Note: NSS = neurological soft signs; Std Diff = standard difference in means; NES = Neurological Evaluation Scale; CNI = Cambridge Neurological Inventory; MC = motor coordination; SI = sensory integration; MSeq = complex motor sequencing; disinhib = disinhibition.

**Q* value heterogeneous, *P* < .05.




Fig. 2. Funnel Plot for the Meta-analysis of Differences in Neurological Soft Signs Motor Coordination Scores Between Schizophrenia Patients and Healthy Controls.

total, MC, and SI associate significantly with cognitive performance collapsed across tasks. In addition, with 10 primary studies reporting data from executive function tasks, the relationship between cognition and NSS total scores is similar in magnitude to the collapsed findings. Correlations between NSS scales and symptom severity (PANSS, BPRS) are presented in tables 5 and 6. Significant relationships were found between NSS total and both total and negative symptoms, with shared variances of 10%–12%. In contrast, while CIs for the mean value for NSS total and positive symptoms excluded 0, the effect size was relatively modest with less than 4% shared variance (figures 5 and 6).

Moderator Variables

Heterogeneity statistics reported in tables 1–6 revealed the presence of significant effect variability in many of the NSS literatures in the study base. Accordingly, it




Fig. 3. Funnel Plot for the Meta-analysis of Differences in Neurological Soft Signs Sensory Integration Scores Between Schizophrenia Patients and Healthy Controls.




Fig. 4. Funnel Plot for the Meta-analysis of Differences in Neurological Soft Signs Complex Motor Sequencing Scores Between Schizophrenia Patients and Healthy Controls.

was of interest to assess moderator variables that may vary with effect magnitudes in these literatures. We examined the effect of several potential moderator variables, including mean age of patient samples, duration of illness, and education. Sample sex proportions, medication status, and symptom severity could not be considered as moderators due to inadequate reporting of relevant data in the primary studies (table 7).

In our analysis, age was a significant moderator of the NSS total score contrast between schizophrenia and control groups, whereby study effect sizes decreased as mean ages of patient samples increased. However, age was not a significant moderator when only NES data were analyzed. Age also moderated the complex motor sequencing (MSeq) but not MC and SI scores contrasting schizophrenic patients and controls. Moreover, age was not a significant moderator for any correlation coefficient




Fig. 5. Funnel Plot for the Meta-analysis of Correlation Between NSS Total Scores and Neurocognitive Test Scores in Schizophrenia Patients.

Table 3. Results of Meta-analyses of Correlations of NSS and Neurocognitive Functions

	Number of Studies	Number of Subjects	Correlation (95% CI)	<i>Q</i> Value
Correlation between NSS total score and cognitive abilities	48	3789	−0.331 (−0.362, −0.299)	54.972
NSS-MC subscale	24	1816	−0.332 (−0.378, −0.283)	28.199
NSS-SI subscale	31	2435	−0.374 (−0.409, −0.339)	30.589
NSS-Mseq subscale	6	489	−0.313 (−0.392, −0.23)	3.253
NSS-disinhib subscale	17	1653	−0.177 (−0.251, −0.101)	37.535*
Correlation between NSS total score and verbal memory	4	383	−0.305 (−0.394, −0.21)	0.955
(WMS-R verbal pairs; paired associate learning; logical memory—immediate, delayed; CVLT)				
NSS-MC subscale	5	423	−0.296 (−0.397, −0.182)	5.71
NSS-SI subscale	6	508	−0.354 (−0.429, −0.274)	2.687
NSS-disinhib subscale	4	338	−0.058 (−0.166, 0.05)	2.037
Correlation between NSS total score and nonverbal memory	6	608	−0.374 (−0.485, −0.252)	13.851*
(WMS-R visual reproduction—immediate, delayed; visual pairs; ROCFT)				
NSS-MC subscale	4	338	−0.396 (−0.483, −0.3)	1.942
NSS-SI subscale	7	554	−0.417 (−0.485, −0.345)	1.748
NSS-Mseq subscale	1	85	−0.3 (−0.482, −0.093)	NA
NSS-disinhib subscale	4	338	−0.117 (−0.241, 0.009)	3.95
Correlation between NSS total score and motor	4	360	−0.299 (−0.392, −0.291)	0.363
(Finger tapping test, Purdue pegboard task)				
Correlation between NSS total score and attention	8	579	−0.292 (−0.382, −0.197)	9.892
(TMT-A, B time; WAIS-R—digit span; reading span test; Stroop; Continuous Performance Test; SART)				
NSS-MC subscale	2	82	−0.274 (−0.6, 0.13)	3.147
NSS-SI subscale	4	252	−0.282 (−0.393, −0.161)	2.058
NSS-Mseq subscale	1	85	−0.26 (−0.448, −0.05)	NA
NSS-disinhib subscale	1	51	−0.015 (−0.289, 0.262)	NA
Correlation between NSS total score and IQ	6	580	−0.336 (−0.443, −0.218)	10.952
(WAIS-R—full scale, verbal, performance; WAIT-III; MWT-B, Ammons Quick Test)				
NSS-MC subscale	4	353	−0.26 (−0.474, −0.017)	12.788*
NSS-SI subscale	5	456	−0.468 (−0.541, −0.388)	4.306
NSS-Mseq subscale	1	79	−0.18 (−0.386, 0.043)	NA
NSS-disinhib subscale	2	246	−0.35 (−0.456, −0.234)	0
Correlation between NSS total score and spatial ability	5	233	−0.268 (−0.386, −0.141)	1.958
(WAIS-R block design, picture arrangement, picture completion)				
NSS-MC subscale	2	62	−0.355 (−0.109, −0.56)	0.017
NSS-SI subscale	1	85	−0.36 (−0.532, −0.159)	0
Correlation between NSS total score and executive function	10	641	−0.361 (−0.428, −0.29)	8.974
(WCST categories achieved, preservative errors, total errors)				
NSS-MC subscale	6	440	−0.335 (−0.417, −0.248)	1.427
NSS-SI subscale	4	246	−0.209 (−0.328, −0.084)	0.486
NSS-Mseq subscale	3	240	−0.377 (−0.482, −0.261)	0.213
NSS-disinhib subscale	4	431	−0.289 (−0.141, 0.424)	7.445
Correlation between NSS total score and language function	4	344	−0.354 (−0.257, 0.445)	2.597
(WAIS-R vocabulary, WRAT-vocabulary, VF)				
NSS-MC subscale	1	118	−0.374 (−0.52, −0.207)	NA
NSS-SI subscale	4	334	−0.384 (−0.473, −0.288)	1.748
NSS-disinhib subscale	1	118	−0.147 (−0.204, −0.089)	NA

Note: NSS = neurological soft signs; MC = motor coordination; SI = sensory integration; MSeq = complex motor sequencing; disinhib = disinhibition; WMS-R = Wechsler Memory Scale-Revised; CVLT = California Verbal Learning Test; ROCFT = Rey Auditory Verbal Learning Test; NA, not available; TMT-A, B = Trail-Making Test—A, B; WAIS-R = Wechsler Adult Intelligence Scale-Revised; WAIT-III = Wechsler Adult Intelligence Test-III; SART = Sustained Attention to Response Test; MWT-B = Mehrfachwahl-Wortschatz-Intelligenz Test; WCST = Wisconsin Card Sorting Test; WRAT = Wide Range Achievement Test; VF = verbal fluency from Controlled Word Association Test; NA = Not Available.

**Q* value heterogeneous, $P < .05$.

Table 4. Adjusted Results of Meta-analyses of Correlations of NSS and Neurocognitive Functions

	Number of Studies	Number of Studies Missing	Adjusted Correlation (Adjusted 95% CI)	Adjusted <i>Q</i> Value
Correlation between NSS total score and cognitive abilities	47	0	—	—
NSS-MC subscale	24	0	—	—
NSS-SI subscale	31	0	—	—
NSS-Mseq subscale	6	0	—	—
NSS-disinhib subscale	17	0	—	—
Correlation between NSS total score and verbal memory (WMS-R verbal pairs; paired associate learning; logical memory—immediate, delayed; CVLT)	4	0 (right side 2)	—	—
NSS-MC subscale	5	0	—	—
NSS-SI subscale	6	2	−0.325 (−0.394, −0.253)	5.248
NSS-disinhib subscale	4	0 (right side 1)	—	—
Correlation between NSS total score and nonverbal memory (WMS-R visual reproduction—immediate, delayed; visual pairs; ROCFT)	6	1	−0.344 (−0.455, −0.221)	18.183
NSS-MC subscale	4	0	—	—
NSS-SI subscale	7	0	—	—
NSS-Mseq subscale	1	NA	—	—
NSS-disinhib subscale	4	2	−0.056 (−0.187, 0.078)	9.192
Correlation between NSS total score and motor (Finger tapping test, Purdue pegboard task)	4	1	−0.29 (−0.378, −0.197)	0.673
Correlation between NSS total score and attention (TMT-A, B time; WAIS-R—digit span; reading span test; Stroop; Continuous Performance Test; SART)	8	0	—	—
NSS-MC subscale	2	NA	—	—
NSS-SI subscale	4	0	—	—
NSS-Mseq subscale	1	NA	—	—
NSS-disinhib subscale	1	NA	—	—
Correlation between NSS total score and IQ (WAIS-R—full scale, verbal, performance; WAIT-III; MWT-B; Ammons Quick Test)	6	0 (right side 2)	—	—
NSS-MC subscale	4	0 (right side 2)	—	—
NSS-SI subscale	5	1	−0.451 (−0.529, −0.367)	6.142
NSS-Mseq subscale	1	NA	—	—
NSS-disinhib subscale	2	NA	—	—
Correlation between NSS total score and spatial ability (WAIS-R block design, picture arrangement, picture completion)	5	0	—	—
NSS-MC subscale	2	NA	—	—
NSS-SI subscale	1	NA	—	—
Correlation between NSS total score and executive function (WCST categories achieved; preservative errors; total errors; SET)	10	2	−0.341 (−0.412, −0.266)	12.746
NSS-MC subscale	6	2	−0.316 (−0.391, −0.237)	2.937
NSS-SI subscale	4	0 (right side 2)	—	—
NSS-Mseq subscale	3	NA	—	—
NSS-disinhib subscale	4	NA	—	—
Correlation between NSS total score and language function (WAIS-R vocabulary; WRAT-vocabulary; VF)	4	1	−0.329 (−0.412, −0.240)	3.946
NSS-MC subscale	1	NA	—	—
NSS-SI subscale	4	1	−0.371 (−0.456, −0.279)	2.461
NSS-disinhib subscale	1	NA	—	—

Note: NSS = neurological soft signs; MC = motor coordination; SI = sensory integration; MSeq = complex motor sequencing; disinhib = disinhibition; WMS-R = Wechsler Memory Scale-Revised; CVLT = California Verbal Learning Test; ROCFT = Rey Auditory Verbal Learning Test; NA, not available; TMT-A, B = Trail-Making Test—A, B; WAIS-R = Wechsler Adult Intelligence Scale-Revised; SART = Sustained Attention to Response Test; WAIT-III = Wechsler Adult Intelligence Test-III; MWT-B = Mehrfachwahl-Wortschatz-Intelligenz Test; WCST = Wisconsin Card Sorting Test; SET = Six-Elements Test; WRAT = Wide Range Achievement Test; VF = verbal fluency from Controlled Word Association Test; NA = Not Available.

Table 5. Results of Meta-analyses of Correlations of NSS and Clinical Symptoms in Schizophrenia Patients

	Number of Studies	Number of Schizophrenic Patients	Corr (95%CI)	<i>Q</i> Value
Correlation between NSS total score and symptom total score	11	696	0.327 (0.213, 0.432)	23.341*
NSS-MC subscale	7	516	0.293 (0.142, 0.430)	18.262*
NSS-SI subscale	7	537	0.237 (0.154, 0.316)	5.323*
NSS-Mseq subscale	7	515	0.216 (0.107, 0.319)	9.171
Correlation between NSS total score and symptom-positive score	10	529	0.192 (0.067, 0.312)	16.578
NSS-MC subscale	6	434	0.153 (0.003, 0.296)	11.493*
NSS-SI subscale	6	434	0.143 (−0.028, 0.306)	14.854*
NSS-Mseq subscale	6	394	0.095 (−0.017, 0.205)	5.989
Correlation between NSS total score and symptom-negative score	15	758	0.346 (0.260, 0.426)	20.728
NSS-MC subscale	7	484	0.252 (0.140, 0.357)	9.183
NSS-SI subscale	6	434	0.194 (0.100, 0.284)	1.627
NSS-Mseq subscale	8	467	0.217 (0.099, 0.330)	11.122

Note: NSS = neurological soft signs; MC = motor coordination; SI = sensory integration; MSeq = complex motor sequencing; Corr = Correlation coefficient.

**Q* value heterogeneous, $P < .05$.

between NSS total and symptoms. In addition, the correlation coefficients between NSS total and IQ increased with the mean age of patient samples.

On the other hand, duration of illness was a significant moderator of the NSS total effect between schizophrenia and control groups. Duration of illness was also a significant moderator for the correlation coefficient between NSS total and IQ. However, duration of illness was not a significant moderator of the correlation between NSS total and symptoms. Finally, education did not moderate any NSS total score contrast between schizo-

phrenia and control samples and was not a significant moderator of correlations between NSS and symptom severity or neurocognitive performance.

In the current study, we would also like to explore the handedness and treatment effect as moderator previously, but many studies reported results without concrete data. Besides, different methods varied across these studies.

There were only 7 studies concerning the association of handedness and soft signs, but 3 of them^{51–53} reported no significant correlations between handedness and NSS; 3

Table 6. Adjusted Results of Meta-analyses of Correlations of NSS and Clinical Symptoms in Schizophrenia Patients

	Number of Studies Missing	Adjusted Std Diff (Adjusted 95% CI)	Adjusted <i>Q</i> Value	Fail-Safe <i>N</i>
Correlation between NSS total score and symptom total score	0	—	—	14
NSS-MC subscale	2	0.224 (0.071, 0.367)	28.755*	6
NSS-SI subscale	2	0.206 (0.125, 0.285)	8.762*	3
NSS-Mseq subscale	2	0.156 (0.030, 0.276)	18.682*	1
Correlation between NSS total score and symptom-positive score	2	0.155 (0.032, 0.273)	20.538	—
NSS-MC subscale	2	0.086 (−0.068, 0.236)	18.769*	NS
NSS-SI subscale	2	0.034 (−0.151, 0.217)	30.806*	NS
NSS-Mseq subscale	1	0.077 (−0.035, 0.187)	7.52	NS
Correlation between NSS total score and symptom-negative score	5	0.296 (0.205, 0.382)	33.183	22
NSS-MC subscale	0	—	—	4
NSS-SI subscale	0	—	—	—
NSS-Mseq subscale	2	0.177 (0.062, 0.287)	15.376	2

Note: NSS = neurological soft signs; Std Diff = standard difference in means; MC = motor coordination; SI = sensory integration; MSeq = complex motor sequencing; NS, not significant.

**Q* value heterogeneous, $P < .05$.




Fig. 6. Funnel Plot for the Meta-analysis of Correlation Between NSS Total Scores and Symptom Scores in Schizophrenia Patients.

studies^{55–57} indicated that there were significant differences between mixed-handed and hand-preference patients. One study⁵⁷ presented a trend for an association between left-handedness and NSS. Among these studies, 2 studies^{51,52} did not report data, while others used different methods (correlation coefficient or *t* test) resulting in insufficient data for us to compute the effect size of handedness on soft signs.

Although there were 30 studies (see table 8) that mentioned the relationship between treatment and NSS, many of them did not mention actual descriptive data or useable data for computation. Among these 30 studies, only 5 studies reported the relevant results. Therefore, we cannot calculate the effect size moderated by treatment. Besides, the majority of studies demonstrated nonsignificant results suggesting that treatment might not be a significant moderator.

In addition, only 2 studies^{79,80} compared the typical and atypical antipsychotics effect on NSS and found nonsignificant difference.

There were very limited studies on the issue of comorbidity on NSS. In the literature, only one study compared the schizophrenia with and without obsessive-compulsive disorder (OCD). The authors indicated that OCD-schizophrenic patients had higher scores on total-NSS than non-OCD-schizophrenic group. Therefore, it is difficult to calculate and combine the results in the current meta-analysis.

Discussion

Our meta-analytic review of NSS in schizophrenia suggests that the illness expresses itself strongly in these basic motor and sensory deficiencies, with mean effects similar or larger in magnitude than those reported in neurobehavioral and neurobiological literatures.^{19,81} The most robust findings were obtained with a summary index of NSS. In addition, we found evidence of associations be-

tween NSS and both cognitive performance and negative symptoms. Moreover, effect sizes were significantly moderated by age and duration of illness. Therefore, the substantial difference between schizophrenia patients and controls suggests that NSS meet one essential criterion (association with illness) of an endophenotype for schizophrenia.

Contrast of NSS Between Schizophrenia Patients and Healthy Controls

Our findings show a large and reliable effect indicating that, on average, a substantial majority of patients (73%) perform outside the range of healthy control subjects on aggregate NSS measures.²¹ The average effect size obtained compares favorably with those reported for cognition, psychophysiology, frontal-temporal brain volumes, and regional physiology.^{24,25,82} The evidence is complicated by the presence of considerable effect heterogeneity, which may reflect the use of difference instruments and patient sample characteristics.⁸³ Hence, more detailed moderator analysis and more comprehensive reporting practices will become increasingly important as the NSS literature expands. Nonetheless, our preliminary quantification of the NSS effect confirms the value of this literature in the search for schizophrenia disease markers and endophenotypes.

Previous studies reported that the frequency of NSS increased with age in a sample of schizophrenic patients.⁸⁴ However, we found that effect sizes based on summary measures of NSS decreased in magnitude with increases in the age of patient samples. This relationship may reflect in part the increased frequency of NSS with age in healthy people.^{36,84} Thus, higher rates of NSS in older control samples may have attenuated the effect found in younger samples. We found an inverse relationship between NSS and age in healthy control samples, which clearly contradicts this interpretation. On the other hand, data from patient samples showed a relation between illness duration and NSS in our study base. This implies that less chronic, and presumably younger, samples may include patients with higher rates of neurological deficit. The implication is partially supported by reports of an inverse relationship between age and verbal memory effect sizes in the neurocognitive literature on schizophrenia.¹ Nonetheless, a similar relationship has not been found in neuroimaging literatures.⁸²

In terms of chronicity-related moderation of the NSS effect, we found no statistically significant difference between first-episode schizophrenia and more chronic patients. However, we did find an association between the overall NSS effect and duration of illness. On the other hand, Chen et al⁸⁴ previously reported a relationship between NSS and duration of illness that became nonsignificant when age and education were taken into account in the analysis. It seems unlikely that

Table 7. Analyses of Potential Moderators of Effect Size of Differences in NSS Total scores Between Patients With Schizophrenia and Healthy Controls

	Number of Studies	Number of Schizophrenic Patients	Number of Healthy Controls	<i>P</i> Value
Contrasting NSS total score of schizophrenia vs controls				
Age (y)	30	2069	1573	.008*
Duration of illness	15	867	675	.045*
Education	22	1451	1127	.67
NSS measured by NES or modified NES				
Age (y)	20	1151	939	.07
Duration of illness	11	437	356	.02*
Education	14	690	572	.16
Chronic/mixed				
Age (y)	23	1687	1255	.05
Duration of illness	10	702	528	.16
Education	17	1286	980	.67
Contrasting NSS-MC score of schizophrenia vs controls				
Age (y)	22	1662	1111	.50
Duration of illness	11	712	543	.86
Education	18	1257	841	.91
NSS measured by NES or modified NES				
Age (y)	13	844	503	.65
Duration of illness	8	318	236	.73
Education	10	486	300	.93
Chronic/mixed				
Age (y)	17	1265	900	.60
Duration of illness	8	543	407	.65
Education	12	930	597	.92
Contrasting NSS-SI score of schizophrenia vs controls				
Age (y)	21	1575	1057	.16
Duration of illness	12	744	575	.13
Education	17	1170	787	.23
NSS measured by NES or modified NES				
Age (y)	14	876	535	.041*
Duration of illness	9	350	268	.21
Education	11	518	332	.54
Chronic/mixed				
Age (y)	16	1239	882	.18
Duration of illness	9	647	500	.07
Education	13	1034	690	.56
Contrasting NSS-Mseq (NES) score of schizophrenia vs controls				
Age (y)	14	855	482	.029*
Duration of illness	8	290	193	.57
Education	12	557	354	.15
Chronic/mixed				
Age (y)	9	519	307	.037*
Duration of illness	5	193	118	.10
Education	8	421	257	.52

Note: NSS = neurological soft signs; NES = Neurological Evaluation Scale; MC = motor coordination; SI = sensory integration; MSeq = complex motor sequencing.

* $P < .05$.

chronicity is a major factor in amplifying or diminishing the NSS-schizophrenia association, but the question should be answerable as the literature expands and provides a more comprehensive study base for moderator analysis.

Several studies^{85,86} have investigated the association between NSS and gender. While Bjorck et al⁸⁵ reported no difference between male and female patients, Duggal et al⁸⁶ illustrated that performance in motor sequencing tasks may be influenced by sex-bound variables.

Table 8. Summary of the Relationships Between Treatment and NSS

Measure	Data	Results	Studies (First Author, Published Year)
Correlation between NSS and treatment	Reported data	Significant Nonsignificant	King, 1991 ⁵⁸ Bartko, 1988 ⁵⁹ ; Lane, 1996 ⁵¹ ; Braun, 1995 ⁴⁶ ; Merriam, 1990 ¹⁴ ; Jahn, 2006 ⁴⁸
	No data	Significant Nonsignificant	Liddle, 1987 ⁶⁰ (included nonsignificant results) Liddle, 1987 ⁶⁰ ; Cox, 1979 ⁶¹ ; Rossi, 1990 ³⁶ ; Schroder, 1992 ⁶² ; Cuesta, 1996 ¹⁰ ; Ismail, 1998 ⁴⁴ ; Flyckt, 1999 ⁶³ ; Arango, 2000 ⁶⁴ ; Chen, 2000 ⁶⁵ ; Biswas, 2007 ⁶⁶
Contrast medication: low NSS vs high NSS	Reported data	Significant Nonsignificant	Flashman, 1996 ¹⁵ Das, 2004 ⁶⁷
	No data	Significant Nonsignificant	— Bersani, 2004 ^{68,69} ; Dazzan, 2004 ⁶⁹
Contrast NSS low dose vs high doses	Reported	Significant Nonsignificant	Boks, 2005 ⁷⁰ (included nonsignificant results) Gureje, 1988 ⁷¹ ; Aydemir, 2005 ⁷² ; Boks, 2005 ⁷⁰
	No data	Nonsignificant	Chen, 2005 ⁷³
Contrast NSS baseline vs posttreated	Reported	Nonsignificant	Scheffer, 2004 ⁷⁴ ; Sevincok, 2006 ⁷⁵
	No data	Nonsignificant	Emsley, 2005 ⁷⁶ ; Mittal, 2007 ⁷⁷
	No data	Significant Nonsignificant	Picchioni, 2006 ⁷⁸ Griffich, 1998 ⁵²

Note: NSS, neurological soft signs.

Unfortunately, we were unable to address gender differences in our meta-analysis because of inadequate reporting of gender composition in the primary studies.

Only 2 studies reported data relevant to the issue of comorbidity and NSS findings. Sevincok et al⁸⁷ compared schizophrenia patients with and without OCD and indicated that OCD-schizophrenia patients had higher scores than non-OCD-schizophrenia patients on total-NSS. In terms of substance abuse co-occurring with the illness, Bersani et al⁸⁸ compared cannabis-consuming and -non-consuming schizophrenia patients. The results showed that NSS were more prevalent in nonconsuming patients. Unfortunately, no conclusions can be reached with such limited data. The question of NSS rates in conditions comorbid with schizophrenia is an important issue that requires more research attention from investigators.

NSS and Neurocognitive and Symptom Scores

This analysis compiled correlation coefficients between NSS and neurocognitive and symptom test scores reported in our primary study base. Cognitive and NSS data share approximately 10% of their variance, implying that these data reflect associated, but distinct, aspects of neurobehavioral function in schizophrenia. Specific relationships were found between sensory and motor soft signs and several aspects of cognitive ability including spatial, executive, and language performance. However, only SI signs were significantly related to IQ measures. This suggests that IQ test performance may require input and coordination of sensory data,

whereas motor system dysfunction associates with disturbances in systems underlying spatial and executive processing.

The correlations between NSS and clinical symptoms were relatively modest but significant. The correlation coefficients between NSS total and total, positive and negative symptoms scores indicate shared variance from 2% to 10%, with the weakest relation between NSS and positive symptom severity. Hence, our results confirm previous studies demonstrating that NSS are more prominent in patients with negative symptoms than in those with positive symptoms.¹⁸

Limitations and Future Research

The current study has several limitations. First, the presence of significant effect variability in some analyses means that average effect sizes may not represent adequately the underlying populations, which may include important subsets of patients.⁸³ This is especially notable in the contrast between patients and controls. Second, potential moderators including age and duration of illness were only coarsely estimated with sample means. Therefore, the relationships between NSS and these factors are not clear and require more refined and detailed analysis. Third, although differences in effect as a function of NSS instrument (NES vs CNI) were examined, a comprehensive analysis of scale differences and score composition was not conducted. Notwithstanding these limitations, this meta-analysis has shown, for the first time, that NSS occur in a majority

of the schizophrenia patient population and are similar to or exceed psychophysiological, cognitive, and neuro-anatomic findings as indicators or correlates of schizophrenic illness. Reporting limitations in the literature with respect to key moderators including gender and chronicity reduce the inferences that can be made about the generality of these findings. These limitations should be addressed through improved reporting practices. In addition, important questions remain concerning prevalence of specific soft signs in the illness and the sources of heterogeneity and effect variability in this population.

Funding

Research Initiation Fund of the 100-Scholar Programme (O7CX031003); Institute of Psychology, Chinese Academy of Sciences (Research Fund KSCX2-YW-R-131); National Science Foundation of China (30770723); National Basic Research Programme (973 Programme No. 2007CB512302).

Acknowledgments

All authors report no competing interests.

References

- Heinrichs RW, Zakzanis KK. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. *Neuropsychology*. 1998;12:426–445.
- de Wilde OM, Bour LJ, Dingemans PM, Koelman JHTM, Linszen DH. A meta-analysis of the P50 studies in patients with schizophrenia and relatives: differences in methodology between research groups. *Schizophr Res*. 2007;97:137–151.
- Heinrichs DW, Buchanan RW. The significance and meaning of neurological signs in schizophrenia. *Am J Psychiatry*. 1988;145:11–18.
- Tsuang MT, Gilbertson MW, Faraone SV. The genetics of schizophrenia: current knowledge and future directions. *Schizophr Res*. 1991;4:157–171.
- Tsuang MT, Faraone SV. The concept of target features in schizophrenia research. *Acta Psychiatr Scand Suppl*. 1999;395:2–11.
- Schröder J, Wenz F, Schad LR, Baudendistel K, Knopp MV. Sensorimotor cortex and supplementary motor area changes in schizophrenia: a study with functional magnetic resonance imaging. *Br J Psychiatry*. 1995;167:197–201.
- Chan RCK, Rao H, Chen EE, Ye B, Zhang C. The neural basis of motor sequencing: an fMRI study of healthy subjects. *Neurosci Lett*. 2006;398:189–194.
- Rao H, Di X, Chan RCK, Ding Y, Ye B, Gao D. A regulation role of the prefrontal cortex in the fist-edge-palm task: evidence from functional connectivity analysis. *Neuroimage*. 2008;41:1345–1351.
- Mohr F, Hubmann W, Cohen R, et al. Neurological soft signs in schizophrenia: assessment and correlates. *Eur Arch Psychiatry Clin Neurosci*. 1996;246:240–248.
- Cuesta MJ, Peralta V, de Leon J. Neurological frontal signs and neuropsychological deficits in schizophrenic patients. *Schizophr Res*. 1996;20:15–20.
- Wong AHC, Voruganti LNP, Heslegrave RJ, Awad AG. Neurocognitive deficits and neurological signs in schizophrenia. *Schizophr Res*. 1997;23:139–146.
- Chen EYH, Lam LCW, Chen RYL, Nguyen DGH, Kwok CL, Au JWY. Neurological signs and sustained attention impairment in schizophrenia. *Eur Arch Psychiatry Clin Neurosci*. 2001;251:1–5.
- Mohr F, Hubmann W, Albus M, et al. Neurological soft signs and neuropsychological performance in patients with first episode schizophrenia. *Psychiatry Res*. 2003;121:21–30.
- Merriam AE, Kay SR, Opler LA, Kushner SF, van Praag HM. Neurological signs and the positive-negative dimension in schizophrenia. *Biol Psychiatry*. 1990;28:181–192.
- Flashman LA, Flaum M, Gupta S, Andreasen NC. Soft signs and neuropsychological performance in schizophrenia. *Am J Psychiatry*. 1996;153:526–532.
- Arango C, Bartko JJ, Gold JM, Buchannan RW. Prediction of neuropsychological performance by neurological signs in schizophrenia. *Am J Psychiatry*. 1999;156:1349–1357.
- Sanders RD, Schuepbach D, Goldstein G, Haas GL, Sweeney JA, Keshavan MS. Relationships between cognitive and neurological performance in neuroleptic-naïve psychosis. *J Neuropsychiatry Clin Neurosci*. 2004;16:480–487.
- Bombin I, Arango C, Buchanan RW. Significance and meaning of neurological signs in schizophrenia: two decades later. *Schizophr Bull*. 2005;31:962–977.
- Chan RCK, Gottesman II. Neurological soft signs as candidate endophenotypes for schizophrenia: a shooting star or a Northern star? *Neurosci Biobehav Rev*. 2008;32:957–971.
- Bombin I, Arango C, Buchanan RW. Assessment tools for soft signs. *Psychiatr Ann*. 2003;33:170–176.
- Heinrichs RW. *In Search of Madness: Schizophrenia and Neuroscience*. New York, NY: Oxford University Press; 2001.
- Heinrichs RW. Meta-analysis and the science of schizophrenia: variant evidence or evidence of variants? *Neurosci Biobehav Rev*. 2004;28:379–394.
- Lipsey MW, Wilson DB. The way in which intervention studies have “personality” and why it is important to meta-analysis. *Eval Health Prof*. 2001;24:236–254.
- Heinrichs RW. The primacy of cognition in schizophrenia. *Am Psychol*. 2005;60:229–242.
- Reichenberg A, Harvey PD. Neuropsychological impairments in schizophrenia: integration of performance-based and brain imaging findings. *Psychol Bull*. 2007;133:833–858.
- Buchannan RW, Heinrichs DW. The Neurological Evaluation Scale (NES): a structured instrument for the assessment of neurological signs in schizophrenia. *Psychiatry Res*. 1989;27:335–350.
- Chen EYH, Shapleske J, Luque R, et al. The Cambridge Neurological Inventory, a clinical instrument for assessment of soft neurological signs. *Psychiatry Res*. 1995;56:183–204.
- Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. *Psychol Rep*. 1962;10:799–812.
- Kay S, Fiszbein A, Opler L. The positive and negative syndrome scale (PANSS) for schizophrenia. *Schizophr Bull*. 1987;13:261–276.
- Andreasen NC. *The Scale for the Assessment of Positive Symptoms (SAPS)*. Iowa City, Iowa: The University of Iowa; 1984.

31. Andreasen NC. *The Scale for the Assessment of Negative Symptoms (SANS)*. Iowa City, Iowa: The University of Iowa; 1984.
32. Wechsler D. *Wechsler Adult Intelligence Scale—Revised: Manual*. New York, NY: The Psychological Corporation; 1981.
33. Wechsler D. *WMS-III Manual*. New York, NY: The Psychological Corporation; 1997.
34. Reitan RM. *Trail Making Test: Manual for Administration, Scoring and Interpretation*. Bloomington: Section of Neuropsychology, Department of Neurology, Indiana University Medical Centre; 1956.
35. Heaton RK. *Wisconsin Card Sorting Test Manual*. Odessa, Fla: Psychological Assessment Resources; 1981.
36. Rossi A, Cataldo SD, Michele VD, et al. Neurological soft signs in schizophrenia. *Br J Psychiatry*. 1990;157:735–739.
37. Borenstein M, Hedges L, Higgins J, Rothstein H. *Comprehensive Meta-analysis*. Englewood, NJ: Biostat, Inc.; 2005.
38. Rosenthal R. The “file drawer problem” and tolerance for null results. *Psychol Bull*. 1979;86:638–641.
39. Sutton AJ, Duval SJ, Tweedie RL, Abrams KR, Jones DR. Empirical assessment of effect of publication bias on meta-analyses. *Br Med J*. 2000;320:1574–1577.
40. Rosenberg MS. The file-drawer problem revisited: a general weighted method for calculating fail-safe numbers in meta-analysis. *Evolution*. 2005;59:464–468.
41. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *Br Med J*. 1997;315:629–634.
42. Duval SJ, Tweedie RL. Practical estimates of the effect of publication bias in meta-analysis. *Australas Epidemiol*. 1998;5:14–17.
43. Ismail B, Cantor-Graae E, McNeil TF. Minor physical anomalies in schizophrenia, cognitive, neurological and other clinical correlates. *J Psychiatr Res*. 2000;34:45–56.
44. Ismail B, Cantor-Graae E, McNeil TF. Neurological abnormalities in schizophrenia, clinical, etiological and demographic correlates. *Schizophr Res*. 1998;30:229–238.
45. Cohen. *Statistical Power Analysis for the Behavioral Sciences (2nd ed)*. New York, NY: Academic Press; 1988.
46. Braun CMJ, Lapierre D. Neurological soft signs in schizophrenia: are they related to negative or positive symptoms, neuropsychological performance, and violence? *Arch Clin Neuropsychol*. 1995;10:489–509.
47. Chen EYH, Chan CK. The Cambridge Neurological Inventory: clinical, demographic, and ethnic correlates. *Psychiatr Ann*. 2003;33:202–210.
48. Jahn T, Hubmann W, Karr M, et al. Motoric neurological soft signs and psychopathological symptoms in schizophrenic psychoses. *Psychiatry Res*. 2006;142:191–199.
49. Quitkin F, Rifkin A, Klein DF. Organicity in schizophrenia with premorbid asociality and emotionally unstable character disorders. *Arch Gen Psychiatry*. 1976;33:845–853.
50. Sanders RD, Keshavan MS, Forman SD, et al. Factor structure of neurologic examination abnormalities in unmedicated schizophrenia. *Psychiatry Res*. 2000;95:237–243.
51. Lane A, Colgan K, Moynihan F, et al. Schizophrenia and neurological soft signs, gender differences in clinical correlates and antecedent factors. *Psychiatry Res*. 1996;64:105–114.
52. Griffiths TD, Sigmundsson T, Takei N, Rowe D, Murray RM. Neurological abnormalities in familial and sporadic schizophrenia. *Brain*. 1998;121:191–203.
53. O'Reilly RL, Lane A, Cernovsky ZZ, O'Callaghan E. Neurological soft signs, minor physical anomalies and handedness in schizophrenia. *Eur J Psychiatry*. 2001;15:189–192.
54. Browne S, Clarke M, Gervin M, et al. Determinants of neurological dysfunction in first episode schizophrenia. *Psychol Med*. 2000;30:1433–1441.
55. Bachmann S, Bottmer C, Schröder J. Neurological soft signs in first-episode schizophrenia: a follow-up study. *Am J Psychiatry*. 2005;162:2337–2343.
56. Whitty P, Clarke M, McTigue O, et al. Diagnostic specificity and predictors of neurological soft signs in schizophrenia, bipolar disorder and other psychoses over the first 4 years of illness. *Schizophr Res*. 2006;86:110–117.
57. Obiols JE, Serrano F, Caparrós B, Subirá S, Barrantes N. Neurological soft signs in adolescents with poor performance on the continuous performance test: markers of liability for schizophrenia spectrum disorders? *Psychiatry Res*. 1999;86:217–228.
58. King DJ, Wilson A, Cooper SJ, Waddington JL. The clinical correlates of neurological soft signs in chronic schizophrenia. *Br J Psychiatry*. 1991;158:770–775.
59. Bartko G, Zador G, Horvath S, Herczeg I. Neurological soft signs in chronic schizophrenic patients: clinical correlates. *Soc Biol Psychiatry*. 1988;24:458–460.
60. Liddle PF. Schizophrenic syndromes, cognitive performance and neurological dysfunction. *Psychol Med*. 1987;17:49–57.
61. Cox SM, Ludwig AM. Neurological soft signs and psychopathology: I. Findings in schizophrenia. *J Nerv Ment Dis*. 1979;167:161–165.
62. Schröder J, Niethammer R, Geider F-J, et al. Neurological soft signs in schizophrenia. *Schizophr Res*. 1992;6:25–30.
63. Flyckt L, Sydowb O, Bjerkenstedta L, Edmana G, Rydinb E, Wiesels F-A. Neurological signs and psychomotor performance in patients with schizophrenia, their relatives and healthy controls. *Psychiatry Res*. 1999;86:113–129.
64. Arango C, Kirkpatrick B, Buchannan RW. Neurological signs and the heterogeneity of schizophrenia. *Am J Psychiatry*. 2000;157:560–565.
65. Chen EYH, Kwok CL, Au JWY, Chen RYL, Lau BST. Progressive deterioration of soft neurological signs in chronic schizophrenia patients. *Acta Psychiatr Scand*. 2000;102:342–349.
66. Biswas P, Malhotra S, Malhotra A, Gupta N. Comparative study of neurological soft signs in schizophrenia with onset in childhood, adolescence. *Acta Psychiatr Scand*. 2007;115:295–303.
67. Das M, Kumari V, Soni W, et al. Neurological soft signs and their relationship to cognitive and clinical efficacy of atypical antipsychotics in schizophrenia. *Schizophr Bull*. 2004;30:241–253.
68. Bersani G, Clemente R, Gherardelli S, Pancheri P. Deficit of executive functions in schizophrenia: relationship to neurological soft signs and psychopathology. *Psychopathology*. 2004;37:118–123.
69. Dazzan P, Morgan KD, Orr KG, et al. The structural brain correlates of neurological soft signs in AESOP first-episode psychoses study. *Brain*. 2004;127:143–153.
70. Boks MPM, Seltén J-P, Leask S, Van den Bosch RJ. The 2-year stability of neurological soft signs after a first episode of non-affective psychosis. *Eur Psychiatry*. 2006;21:288–290.
71. Gureje O. Neurological soft signs in Nigerian schizophrenics: a controlled study. *Acta Psychiatr Scand*. 1988;78:505–509.

72. Aydemir C, Goka E, Kisa C, Kurt A, Yuksel FV. Dyskinesia and soft neurological signs in schizophrenia: a comparative study. *Int J Psychiatry Clin Pract.* 2005;9:238–243.
73. Chen EY, Hui CL, Chan RC, et al. A 3-year prospective study of neurological soft signs in first-episode schizophrenia. *Schizophr Res.* 2005;75:45–54.
74. Scheffer RE. Abnormal neurological signs at the onset of psychosis. *Schizophr Res.* 2004;70:19–26.
75. Sevincok L, Topaloglu B. Neurological soft signs and positive treatment response to olanzapine in chronic schizophrenia. *Prog Neuropsychopharmacol Biol Psychiatry.* 2006;30:141–143.
76. Emsley R, Turnera HJ, Oosthuizen PP, Carr J. Neurological abnormalities in first-episode schizophrenia: temporal stability and clinical and outcome correlates. *Schizophr Res.* 2005;75:35–44.
77. Mittal VA, Hasenkamp W, Sanfilipo M, et al. Relation of neurological soft signs to psychiatric symptoms in schizophrenia. *Schizophr Res.* 2007;94:37–44.
78. Picchioni MM, Touloupoulou T, Landau S, Davies N, Ribchester T, Murray RM. Neurological abnormalities in schizophrenic twins. *Biol Psychiatry.* 2006;59:341–348.
79. Bersani G, Gherardelli S, Clemente R, et al. Neurologic soft signs in schizophrenic patients treated with conventional and atypical antipsychotics. *J Clin Psychopharmacol.* 2005;25:372–375.
80. Boks MPM, Liddle PF, Burgerhof JGM, Kneegting R, Bosch R-Jvd. Neurological soft signs discriminating mood disorders from first episode schizophrenia. *Acta Psychiatr Scand.* 2004;110:29–35.
81. Gottesman II, Gould TD. The endophenotype concept in psychiatry: etymology and strategic intentions. *Am J Psychiatry.* 2003;160:636–645.
82. Davidson L, Heinrichs RW. Quantification of brain imaging findings on the frontal and temporal lobes in schizophrenia: a meta-analysis. *Psychiatry Res.* 2003;122:69–87.
83. Hallmayer JF, Kalaydjieva L, Badcock J, et al. Genetic evidence for a distinct subtype of schizophrenia characterized by pervasive cognitive deficit. *Am J Hum Genet.* 2005;77:468–476.
84. Chen EYH, Lam LCW, Chen RYL, Nguyen DGH. Neurological signs, age, and illness duration in schizophrenia. *J Nerv Ment Dis.* 1996;184:339–345.
85. Bjorck RV, Sjalín M, Nordin C. Neurological soft signs in schizophrenic patients: influence of age, age at onset, sex, and family history of schizophrenia. *Nord J Psychiatry.* 2000;54:437–440.
86. Duggal HS, Muddasani S, Keshavan MS. Insular volumes in first-episode schizophrenia: gender effect. *Schizophr Res.* 2005;73:113–120.
87. Sevincok L, Akoglu A, Topaloglu B, Aslantas H. Neurological soft signs in schizophrenic patients with obsessive-compulsive disorder. *Psychiatry Clin Neurosci.* 2004;58:274–278.
88. Bersani G, Orlandi V, Gherardelli S, Pancheri P. Cannabis and neurological soft signs in schizophrenia: absence of relationship and influence on psychopathology. *Psychopathology.* 2002;35:289–295.
89. Krebs MO, GutFayand A, Bourdel MC, Dischamps, J, Olie JP. Validity and factorial structure of a standardized examination for neurological soft-signs in schizophrenia. *Schizophr Res.* 2000;45:245–260.

Appendix I: NSS Scales

Scale	Items
NES ²⁶	MC: intention tremor, balance, gait, hopping, finger-thumb opposition, disidiadochokinesia, finger-to-nose test SI: bilateral extinction, audiovisual integration, graphaesthesia, stereognosis, R-L confusion extinction Mseq: fist-edge-palm, fist-ring, Ozeretsky, go/no-go, rhythm tapping
CNI ²⁷	MC: finger tapping (L/R), finger-thumb opposition (L/R), fist-edge-palm, Ozeretsky SI: extinction, finger agnosia, stereognosis, graphaesthesia, L-R orientation Disinhib: saccade blink, saccade head, wink, mirror movement of fist-edge-palm, mirror movement of disidiadochokinesia (L/R), go/no-go test
23 items from Krebs ⁸⁹	Gait, tandem walk, Romberg (balance), standing heel-to-toe, tongue protrusion, finger-to-nose, RL confusion, RL recognition, hand-face, lateral preference, apraxia, alternative movement of foot speed (R/L), foot dysrhythmia (R/L), alternative movements of hand speed (R/L), hand dysrhythmia (R/L), finger opposition (R/L), fist-edge-palm (R/L), mirror movements (R/L), abnormal movement and posture, RL asymmetry, stereognosis, constructive apraxia, graphaesthesia (R/L)
Heidelberg Scale ⁶²	Station and gait, tandem walking, R/L orientation, speech articulation, primitive reflexes, Ozeretsky test, pronation/supination, diadochokinesis, finger-to-thumb opposition, 2-point discrimination, fist-edge-palm, finger-to-nose, face-hand sensory, graphaesthesia, stereognosis, mirror movements, arm-holding test

Note: R, right; L, left; disinhib, disinhibition.

Appendix II: Studies Included in Meta-analysis

- Arango C, Bartko JJ, Gold JM, Buchannan RW. Prediction of neuropsychological performance by neurological signs in schizophrenia. *Am J Psychiatry*. 1999;156:1349–1357.
- Aydemir C, Goka E, Kisa C, Kurt A, Yuksel FV. Dyskinesia and soft neurological signs in schizophrenia: a comparative study. *Int J Psychiatry Clin Pract*. 2005;9:238–243.
- Bachmann S, Bottmer C, Schröder J. Neurological soft signs in first-episode schizophrenia: a follow-up study. *Am J Psychiatry*. 2005;162:2337–2343.
- Bersani G, Orlandi V, Gherardelli S, Pancheri P. Cannabis and neurological soft signs in schizophrenia: absence of relationship and influence on psychopathology. *Psychopathology*. 2002;35:289–295.
- Biswas P, Malhotra S, Malhotra A, Gupta N. Comparative study of neurological soft signs in schizophrenia with onset in childhood, adolescence. *Acta Psychiatr Scand*. 2007;115:295–303.
- Bolton D, Gibb W, Lees A, et al. Neurological soft signs in obsessive compulsive disorder: standardized assessment and comparison with schizophrenia. *Behav Neurol*. 1998;11:197–204.
- Braun CMJ, Lapierre D. Neurological soft signs in schizophrenia: are they related to negative or positive symptoms, neuropsychological performance, and violence? *Arch Clin Neuropsychol*. 1995;10:489–509.
- Buchanan RW, Heinrichs DW. The Neurological Evaluation Scale (NES): a structured instrument for the assessment of neurological signs in schizophrenia. *Psychiatry Res*. 1989;27:335–350.
- Chan RCK, Wang L, Chen EE, et al. Neurological soft signs and their relationships to neurocognitive functions: a re-visit with the structural equation modeling design. Submitted.
- Chan R, Chen E. Executive dysfunctions and neurological manifestations in schizophrenia. *Hong Kong J Psychiatry*. 2004;14:2–6.
- Chan RCK, Wang Y, Ma Z, et al. Neurological soft signs and neurocognitive deficits along the continuum of schizophrenia spectrum disorders. Submitted.
- Chen EYH, Shapleske J, Luque R, et al. The Cambridge Neurological Inventory, a clinical instrument for assessment of soft neurological signs. *Psychiatry Res*. 1995;56:183–204.
- Chen EYH, Lam LCW, Chen RYL, Nguyen DGH. Neurological signs, age, and illness duration in schizophrenia. *J Nerv Ment Dis*. 1996;184:339–345.
- Chen EYH, Kwok CL, Au JWY, Chen RYL, Lau BST. Progressive deterioration of soft neurological signs in chronic schizophrenia patients. *Acta Psychiatr Scand*. 2000;102:342–349.
- Chen YLR, Chen YHE, Mak FL. Soft neurological signs in schizophrenic patients and their nonpsychotic siblings. *J Nerv Ment Dis*. 2000;188:84–89.
- Chen EYH, Chan CK. The Cambridge Neurological Inventory: clinical, demographic, and ethnic correlates. *Psychiatr Ann*. 2003;33:202–210.
- Chen EYH, Hui CLM, Chan RCK, et al. A 3-year prospective study of neurological soft signs in first-episode schizophrenia. *Schizophr Res*. 2005;75:45–54.
- Compton MT, Bollini AM, Mack LM, et al. Neurological soft signs and minor physical anomalies in patients with schizophrenia and related disorders, their first degree biological relatives, and non-psychiatric controls. *Schizophr Res*. 2007;94:64–73.
- Cuesta MJ, Peralta V, de Leon J. Neurological frontal signs and neuropsychological deficits in schizophrenic patients. *Schizophr Res*. 1996;20:15–20.
- Cuesta MJ, Peralta V, Zarzuela A, Calvo R, García M, Serrano F. Neurological soft-signs in psychosis: threshold criteria for discriminating normal controls and for predicting cognitive impairment. *Schizophr Res*. 2002;58:263–271.
- Dazzan P, Morgan KD, Orr KG, et al. The structural brain correlates of neurological soft signs in AESOP first-episode psychoses study. *Brain*. 2004;127:143–153.
- Egan MF, Hyde TM, Bonomo JB, et al. Relative risk of neurological signs in siblings of patients with schizophrenia. *Am J Psychiatry*. 2001;158:1827–1834.
- Flashman LA, Flaum M, Gupta S, Andreasen NC. Soft signs and neuropsychological performance in schizophrenia. *Am J Psychiatry*. 1996;153:526–532.
- Gourion D, Goldberger C, Bourdel MC, et al. Neurological soft-signs and minor physical anomalies in schizophrenia: differential transmission within families. *Schizophr Res*. 2003;63:181–187.
- Gourion D, Goldberger C, Olie JP, Löö H, Krebs MO. Neurological and morphological anomalies and the genetic liability to schizophrenia: a composite phenotype. *Schizophr Res*. 2004;67:23–31.
- Jahn T, Hubmann W, Karr M, et al. Motoric neurological soft signs and psychopathological symptoms in schizophrenic psychoses. *Psychiatry Res*. 2006;142:191–199.
- John JP, Arunachalam V, Ratnam B, Isaac MK. Expanding the schizophrenia phenotype: a composite evaluation of neurodevelopmental markers. *Compr Psychiatry*. 2008;49:78–86.
- Keshavan MS, Sanders RD, Sweeney JA, et al. Diagnostic specificity and neuroanatomical validity of neurological abnormalities in first-episode psychoses. *Am J Psychiatry*. 2003;160:1298–1304.
- Krebs MO, Fayand AG, Bourdel MC, Dischamps J, Olie JP. Validity and factorial structure of a standardized examination for neurological soft-signs in schizophrenia. *Schizophr Res*. 2000;45:245–260.
- Lindberg N, Tani P, Stenberg JH, Appelberg B, Heiskanen TP, MattiVirkkunen. Neurological soft signs in homicidal men with antisocial personality disorder. *Eur Psychiatry*. 2004;19:433–437.
- Merriam AE, Kay SR, Opler LA, Kushner SF, van Praag HM. Neurological Signs and the Positive-Negative Dimension in Schizophrenia. *Biol Psychiatry*. 1990;28:181–192.
- Mittal VA, Hasenkamp W, Sanfilippo M, et al. Relation of neurological soft signs to psychiatric symptoms in schizophrenia. *Schizophr Res*. 2007;94:37–44.
- Mohr F, Hubmann W, Albus M, et al. Neurological soft signs and neuropsychological performance in patients with first episode schizophrenia. *Psychiatry Res*. 2003;121:21–30.
- Picchioni MM, Touloupoulou T, Landau S, Davies N, Ribchester T, Murray RM. Neurological abnormalities in schizophrenic twins. *Biol Psychiatry*. 2006;59:341–348.
- Poole JH, Ober BA, Shenaut GK, Vinogradov S. Independent frontal-system deficits in schizophrenia: cognitive, clinical, and adaptive implications. *Psychiatry Res*. 1999;85:161–176.
- Prikryl R, Ceskova E, Kasperek T, Kucerova H. Neurological soft signs, clinical symptoms and treatment reactivity in patients suffering from first episode schizophrenia. *J Psychiatr Res*. 2006;40:141–146.
- Quitkin F, Rifkin A, Klein DF. Organicity in schizophrenia with premorbid asociality and emotionally unstable character disorders. *Arch Gen Psychiatry*. 1976;33:845–853.
- Rossi A, Cataldo SD, Michele VD, et al. Neurological soft signs in schizophrenia. *Br J Psychiatry*. 1990;157:735–739.
- Sanders RD, Keshavan MS, Forman SD, et al. Factor structure of neurologic examination abnormalities in unmedicated schizophrenia. *Psychiatry Res*. 2000;95:237–243.
- Sanders RD, Schuepbach D, Goldstein G, Haas GL, Sweeney JA, Keshavan MS. Relationships between cognitive and neurolog-

- ical performance in neuroleptic-naïve psychosis. *J Neuropsychiatry Clin Neurosci.* 2004;16:480–487.
- Scheffer RE. Abnormal neurological signs at the onset of psychosis. *Schizophr Res.* 2004;70:19–26.
- Schröder J, Niethammer R, Geider FJ, et al. Neurological soft signs in schizophrenia. *Schizophr Res.* 1992;6:25–30.
- Schröder J, Essig M, Baudendistel K, et al. Motor dysfunction and sensorimotor cortex activation changes in schizophrenia: a study with functional magnetic resonance imaging. *Neuroimage.* 1999;9:81–89.
- Sevincok L, Akoglu A, Topaloglu B, Aslantas H. Neurological soft signs in schizophrenic patients with obsessive-compulsive disorder. *Psychiatry Clin Neurosci.* 2004;58:274–279.
- Sevincok L, Topaloglu B. Neurological soft signs and positive treatment response to olanzapine in chronic schizophrenia. *Prog Neuropsychopharmacol Biol Psychiatry.* 2006;30:141–143.
- Shibre T, Kebede D, Alem A, et al. Neurological soft signs (NSS) in 200 treatment-naïve cases with schizophrenia: a community-based study in a rural setting. *Nord J Psychiatry.* 2002;56:425–431.
- Smith RC, Kadewari RP. Neurological soft signs and response to risperidone in chronic schizophrenia. *Biol Psychiatry.* 1996;40:1056–1059.
- Smith RC, Hussain MI, Chowdhury SA, Stearns A. Stability of neurological soft signs in chronically hospitalized schizophrenic patients. *J Neuropsychiatry Clin Neurosci.* 1999;11:91–96.
- Stedman TJ, Clair AL. Neuropsychological, neurological and symptom correlates of impaired olfactory identification in schizophrenia. *Schizophr Res.* 1998;32:23–30.
- Szendi In, Kissb M, Racsmányd MI, et al. Correlations between clinical symptoms, working memory functions and structural brain abnormalities in men with schizophrenia. *Psychiatry Res.* 2006;147:47–55.
- Varambally S, Venkatasubramanian G, Thirthalli J, Janakiramaiah N, Gangadhar BN. Cerebellar and other neurological soft signs in antipsychotic-naïve schizophrenia. *Acta Psychiatr Scand.* 2006;114:352–356.
- Velligan DI, Ritch JL, Sui D, DiCocco M, Huntzinger CD. Frontal systems behavior scale in schizophrenia: relationships with psychiatric symptomatology, cognition and adaptive function. *Psychiatry Res.* 2002;113:227–236.
- Venkatasubramanian G, Latha V, Gangadhar BN, et al. Neurological soft signs in never-treated schizophrenia. *Acta Psychiatr Scand.* 2003;108:144–146.
- Whitty P, Clarke M, Browne S, et al. Prospective evaluation of neurological soft signs in first-episode schizophrenia in relation to psychopathology: state versus trait phenomena. *Psychol Med.* 2003;33:1479–1484.
- Wong AHC, Voruganti LNP, Heslegrave RJ, Awad AG. Neurocognitive deficits and neurological signs in schizophrenia. *Schizophr Res.* 1997;23:139–146.
- Yazici AH, Demir B, Yazici KM, Gogus A. Neurological soft signs in schizophrenic patients and their nonpsychotic siblings. *Schizophr Res.* 2002;58:241–246.